Iberiabank Corp cut its stake in shares of Stryker Corporation (NYSE:SYK) by 4.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,311 shares of the medical technology company’s stock after selling 254 shares during the period. Iberiabank Corp’s holdings in Stryker Corporation were worth $737,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Bollard Group LLC increased its stake in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock valued at $109,000 after buying an additional 3 shares in the last quarter. Baystate Wealth Management LLC increased its stake in shares of Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock valued at $139,000 after buying an additional 22 shares in the last quarter. Guardian Life Insurance Co. of America increased its stake in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after buying an additional 9 shares in the last quarter. Assetmark Inc. increased its stake in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after buying an additional 4 shares in the last quarter. Finally, Mosaic Family Wealth LLC increased its stake in shares of Stryker Corporation by 3.5% in the first quarter. Mosaic Family Wealth LLC now owns 1,300 shares of the medical technology company’s stock valued at $171,000 after buying an additional 44 shares in the last quarter. Institutional investors and hedge funds own 73.79% of the company’s stock.

Shares of Stryker Corporation (NYSE SYK) traded down 0.74% during mid-day trading on Friday, hitting $144.29. The company’s stock had a trading volume of 1,673,285 shares. The company has a market cap of $53.97 billion, a price-to-earnings ratio of 32.21 and a beta of 0.80. The company has a 50-day moving average of $144.61 and a 200 day moving average of $136.38. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84.

Stryker Corporation (NYSE:SYK) last posted its earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.98 billion. During the same quarter in the prior year, the business earned $1.39 earnings per share. The firm’s revenue for the quarter was up 6.1% on a year-over-year basis. On average, analysts expect that Stryker Corporation will post $6.50 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be paid a $0.425 dividend. This represents a $1.70 annualized dividend and a dividend yield of 1.18%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s dividend payout ratio (DPR) is currently 37.95%.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/20/stryker-corporation-syk-shares-sold-by-iberiabank-corp.html.

Several equities research analysts have recently commented on SYK shares. Needham & Company LLC reaffirmed a “sell” rating on shares of Stryker Corporation in a report on Wednesday, April 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $140.00 target price (up from $135.00) on shares of Stryker Corporation in a report on Wednesday, April 26th. Cowen and Company set a $150.00 target price on Stryker Corporation and gave the company an “outperform” rating in a report on Wednesday, April 26th. Barclays PLC reaffirmed a “sell” rating and set a $133.00 target price on shares of Stryker Corporation in a report on Thursday, April 27th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $148.00 target price (up from $135.00) on shares of Stryker Corporation in a report on Saturday, April 29th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $144.03.

In other Stryker Corporation news, insider David Floyd sold 19,305 shares of the company’s stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total transaction of $2,790,730.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the sale, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,810 shares of company stock valued at $4,754,958. 7.40% of the stock is currently owned by corporate insiders.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.